Coya announced a peer-reviewed publication in Brain Communications reporting biomarker findings from blood samples collected from 27 frontotemporal dementia patients and 25 age-matched healthy controls. The study found reduced regulatory T-cell suppressive function in frontotemporal dementia patients and increased levels of TNFα in plasma compared with controls. It also reported higher circulating chemokines in patients, including CXCL12 and CXCL10. The announcement said these findings are consistent with results that were already reported from an investigator-initiated study of low-dose IL-2 plus CTLA-4 Ig in frontotemporal dementia patients. In that earlier study, treatment was associated with increased regulatory T-cell number and function by week 2 and stable MoCA scores over a 22-week treatment period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603180800BIZWIRE_USPR_____20260318_BW067300) on March 18, 2026, and is solely responsible for the information contained therein.